Marc Tessier-Lavigne, Director at Denali Therapeutics Inc. (DNLI), sold 93,526 shares at $60.03 ($5.6M) on 2021-05-24, disclosed to the SEC on 2021-05-24.
Open-market sale of $5.6M DNLI by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $60.13 | 37,957 | $2.3M | 40.6% |
| 2 | $60.13 | 37,957 | $2.3M | 40.6% |
| 3 | $60.03 | 8,806 | $529K | 9.4% |
| 4 | $60.03 | 8,806 | $529K | 9.4% |
| Total | $60.11 avg | 93,526 | $5.6M | 100% |
| Filing → |
| REGN | SELL | 2022-10-03 | $10.2M | — | Filing → |
| DNLI | SELL | 2022-09-30 | $1.2M | — | Filing → |
| DNLI | SELL | 2022-08-25 | $632K | — | Filing → |